Moreover, combining FDA‐approved HDAC6 inhibitors currently under clinical investigation with METTL3 inhibitors may offer a promising treatment strategy for cancers characterized by ciliary disorders, potentialy expanding therapeutic options. This evidence concerns the gene HDAC6 and cancer.